title: Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
abstract: The bromodomain and extraterminal (BET) protein BRD2-4 inhibitors hold therapeutic promise in preclinical models of hematologic malignancies. However, translation of these data to molecules suitable for clinical development has yet to be accomplished. Herein we expand the mechanistic understanding of BET inhibitors in multiple myeloma by using the chemical probe molecule I-BET151. I-BET151 induces apoptosis and exerts strong antiproliferative effect in vitro and in vivo. This is associated with contrasting effects on oncogenic MYC and HEXIM1, an inhibitor of the transcriptional activator P-TEFb. I-BET151 causes transcriptional repression of MYC and MYC-dependent programs by abrogating recruitment to the chromatin of the P-TEFb component CDK9 in a BRD2-4-dependent manner. In contrast, transcriptional upregulation of HEXIM1 is BRD2-4 independent. Finally, preclinical studies show that I-BET762 has a favorable pharmacologic profile as an oral agent and that it inhibits myeloma cell proliferation, resulting in survival advantage in a systemic myeloma xenograft model. These data provide a strong rationale for extending the clinical testing of the novel antimyeloma agent I-BET762 and reveal insights into biologic pathways required for myeloma cell proliferation.
authors: Centre for Haematology, Department of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom;
authors: Aristeidis
authors: A
authors: Chaidos
authors: Valentina
authors: V
authors: Caputo
authors: Katerina
authors: K
authors: Gouvedenou
authors: Binbin
authors: B
authors: Liu
authors: Ilaria
authors: I
authors: Marigo
authors: Mohammed Suhail
authors: MS
authors: Chaudhry
authors: Antonia
authors: A
authors: Rotolo
authors: David F
authors: DF
authors: Tough
authors: Nicholas N
authors: NN
authors: Smithers
authors: Anna K
authors: AK
authors: Bassil
authors: Trevor D
authors: TD
authors: Chapman
authors: Nicola R
authors: NR
authors: Harker
authors: Olena
authors: O
authors: Barbash
authors: Peter
authors: P
authors: Tummino
authors: Niam
authors: N
authors: Al-Mahdi
authors: Andrea C
authors: AC
authors: Haynes
authors: Leanne
authors: L
authors: Cutler
authors: BaoChau
authors: B
authors: Le
authors: Amin
authors: A
authors: Rahemtulla
authors: Irene
authors: I
authors: Roberts
authors: Maurits
authors: M
authors: Kleijnen
authors: Jason J
authors: JJ
authors: Witherington
authors: Nigel J
authors: NJ
authors: Parr
authors: Rab K
authors: RK
authors: Prinjha
authors: Anastasios
authors: A
authors: Karadimitris
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001569:Benzodiazepines / Q000494:pharmacology / Q000627:therapeutic use*; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D015536:Down-Regulation / Q000187:drug effects; D006576:Heterocyclic Compounds, 4 or More Rings / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics; D016601:RNA-Binding Proteins / Q000235:genetics; D014157:Transcription Factors; D015533:Transcriptional Activation / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; C568713:GSK1210151A; C476123:HEXIM1 protein, human; D006576:Heterocyclic Compounds, 4 or More Rings; D016271:Proto-Oncogene Proteins c-myc; D016601:RNA-Binding Proteins; D014157:Transcription Factors; D001569:Benzodiazepines; C554645:molibresib